Date: 2015-12-18
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Isis Pharmaceuticals now Ionis Pharmaceuticals (USA - CA)
Therapeutic area:
Type agreement: name change
Action mechanism:
Disease:
Details: * On December 18, 2015,Isis Pharmaceuticals announced that the company has changed its name to Ionis Pharmaceuticals. Ionis Pharmaceuticals is an original name that the Company has chosen to represent its innovative culture and heritage as both the pioneer and leader in the RNA-targeted therapeutic space for the past 26 years. Ionis is focused on bringing its late-stage Phase 3 drugs, nusinersen, volanesorsen and IONIS-TTRRx to the market and advancing its pipeline of high value drugs that have the potential to be first-in-class or best-in-class drugs to treat patients with life-threatening or serious diseases. In conjunction with the corporate name change, the Company will trade on the NASDAQ Global Select Market under the new ticker symbol \"IONS\". The new ticker symbol will become effective at the open of the market on December 22, 2015.
Financial terms:
Latest news:
